Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Mr. Enrico Cañal Bruland, General Manager, Novo Nordisk Pharma (Thailand ... support in empowering people with diabetes to lead fulfilling lives, pursue education, careers, and reach their ...

Novo Nordisk is Europe’s most valuable listed company, having found huge success with its weight-loss and type 2 diabetes injections Wegovy and Ozempic. The company expects to significantly ...

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers. It needs next generation innovation and growth in emerging markets to keep ahead of competitors ...

There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes ... according to Novo Nordisk. "Up to 85% of the materials in every pen ...

“With the support of Novo Holdings and access to additional resources ... 1 drugs for diabetes and obesity, manufacturing capacity has been a constant area of focus for Novo Nordisk and Eli ...

The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...

David Jagielski (Novo Nordisk): It's been a tough 2024 for drugmaker Novo Nordisk. Entering this week, its shares were down 14% as the company behind the popular diabetes drug Ozempic has been ...

Novo Holdings, the parent company of Novo Nordisk, can proceed with its planned ... In a Dec. 13 letter, the Health Resources & Services Administration said that if Sanofi proceeds with its ...

DelveInsight's Mild Cognitive Impairment Market Insights report includes a comprehensive understanding of current treatment ...

According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...